Key Takeaways and Future Directions: Genomic Assays in Breast Cancer Treatment

Clinical Case Scenarios and Concluding Remarks

Main Discussion Topics:

• Case scenario discussions for node-positive postmenopausal patients
• Approaches to large tumors in smaller breasts, with focus on breast conservation
• Synthesis of key takeaways about genomic testing utility

Key Points for Physicians:

• For a 64-year-old healthy patient with 1 positive lymph node and T1c tumor, a 21-gene assay would guide treatment decisions.
• For larger tumors in smaller breasts, genomic testing can help determine whether neoadjuvant chemotherapy or endocrine therapy would be more effective.
• Genomic assays have dramatically reduced unnecessary chemotherapy use while enabling tailored treatment approaches.

Notable Insights:

• Genomic testing results consistently outperform clinician predictions about tumor biology.
• For borderline breast conservation candidates, neoadjuvant endocrine therapy may be effective for select patients with favorable biology.
• Patient-specific factors including reconstruction timing, genetic testing results, and personal preferences influence the treatment decision process

Clinical Significance: Genomic testing has transformed breast cancer care by enabling personalized treatment decisions that balance efficacy and toxicity considerations, significantly reducing overtreatment while identifying patients who truly benefit from more aggressive approaches.